[go: up one dir, main page]

WO2008013928A3 - Treatment of cancer with interferon gene delivery in combination with a tgf-beta inhibitor - Google Patents

Treatment of cancer with interferon gene delivery in combination with a tgf-beta inhibitor Download PDF

Info

Publication number
WO2008013928A3
WO2008013928A3 PCT/US2007/016880 US2007016880W WO2008013928A3 WO 2008013928 A3 WO2008013928 A3 WO 2008013928A3 US 2007016880 W US2007016880 W US 2007016880W WO 2008013928 A3 WO2008013928 A3 WO 2008013928A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
tgf
cancer
combination
gene delivery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/016880
Other languages
French (fr)
Other versions
WO2008013928A2 (en
Inventor
Michael Parr
Leona Ling
Steven Albelda
Samuel Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
University of Pennsylvania Penn
Biogen MA Inc
Original Assignee
University of Pennsylvania Penn
Biogen Idec Inc
Biogen Idec MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania Penn, Biogen Idec Inc, Biogen Idec MA Inc filed Critical University of Pennsylvania Penn
Publication of WO2008013928A2 publication Critical patent/WO2008013928A2/en
Publication of WO2008013928A3 publication Critical patent/WO2008013928A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The invention provides methods for cancer treatment, comprising administering to a subject in need of the treatment a combination therapy which comprises (a) administration of a TGF-β inhibitor and (b) a vector comprising an isolated polynucleotide which encodes an interferon polypeptide.
PCT/US2007/016880 2006-07-28 2007-07-27 Treatment of cancer with interferon gene delivery in combination with a tgf-beta inhibitor Ceased WO2008013928A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83377206P 2006-07-28 2006-07-28
US60/833,772 2006-07-28

Publications (2)

Publication Number Publication Date
WO2008013928A2 WO2008013928A2 (en) 2008-01-31
WO2008013928A3 true WO2008013928A3 (en) 2008-10-30

Family

ID=38982092

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/016880 Ceased WO2008013928A2 (en) 2006-07-28 2007-07-27 Treatment of cancer with interferon gene delivery in combination with a tgf-beta inhibitor

Country Status (1)

Country Link
WO (1) WO2008013928A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7994185B2 (en) 2008-05-06 2011-08-09 Glaxo Smith Kline LLC Benzene sulfonamide thiazole and oxazole compounds

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011008261A (en) * 2009-02-05 2011-09-01 Digna Biotech Sl Pharmaceutical compositions comprising tgf- î²1 inhibitor peptides.
WO2012029792A1 (en) * 2010-08-30 2012-03-08 独立行政法人理化学研究所 Compound having activity for inhibiting tgf-β receptor activation, method for screening same, and composition for prevention or treatment of hepatitis c virus-induced diseases
CA3209779A1 (en) 2021-02-01 2022-08-04 Regenxbio Inc. Gene therapy for neuronal ceroid lipofuscinoses

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHEN ET AL.: "Adeno-associated virus mediated interferon-gamma inhibits the progression of heptic fibrosis in vitro and in vivo", WORLD GARTROENTEROL., vol. 12, no. 26, 2005, pages 4045 - 4051, XP008103910 *
CURTIN ET AL.: "Combining cytotoxic and immune-mediated gene therapy to treat brain tumor", CURR. TOP. MED. CHEM., vol. 5, no. 12, 2005, pages 1151 - 1170 *
HJELMELAND ET AL.: "SB-431542, a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glimo cell line proliferation and mitility", MOL. CANCER THER., vol. 3, no. 6, 2004, pages 737 - 745 *
ZHANG ET AL.: "Blockage of transforming growth factor-beta signaling in tumor-reactive CD8+ T cells activates the antitumor immune response cycle", MOL. CANCER THER., vol. 5, no. 7, 2006, pages 1733 - 1745 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7994185B2 (en) 2008-05-06 2011-08-09 Glaxo Smith Kline LLC Benzene sulfonamide thiazole and oxazole compounds
US8415345B2 (en) 2008-05-06 2013-04-09 Glaxo SmithKline LLC Benzene sulfonamide thiazole and oxazole compounds
US8642759B2 (en) 2008-05-06 2014-02-04 Glaxosmithkline Llc Benzene sulfonamide thiazole and oxazole compounds

Also Published As

Publication number Publication date
WO2008013928A2 (en) 2008-01-31

Similar Documents

Publication Publication Date Title
WO2007113648A3 (en) Ctla4 antibody combination therapy
WO2011053991A3 (en) Vault complexes for cytokine delivery
AU2018256546A1 (en) Combination therapy with peptide epoxyketones
WO2007146426A3 (en) Nanoshells for drug delivery
WO2008143954A3 (en) Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
WO2008091375A3 (en) Attenuated salmonella as a delivery system for sirna-based tumor therapy
IL172223A0 (en) Drug delivery systems for tumor targeting ngr-molecules and uses thereof
WO2008060510A3 (en) Zinc finger nuclease for targeting the human glucocorticoid receptor locus
WO2007064945A3 (en) Cancer therapies and pharmaceutical compositions used therein
EP3895725A3 (en) A method for treating tumor by using recombinant interferon with changed spatial configuration
MX2015000016A (en) Protozoan variant-specific surface proteins (vsp) as carriers for oral drug delivery.
WO2008016633A3 (en) Combination therapy
WO2006041641A3 (en) Therapeutic agents with decreased toxicity
WO2007092944A3 (en) Compositions and methods involving gene therapy and proteasome modulation
WO2007093373A3 (en) Branched multimeric peptides for tumor diagnosis and therapy
WO2008040190A8 (en) Small peptides for anti-angiogenesis and use thereof
WO2008013928A3 (en) Treatment of cancer with interferon gene delivery in combination with a tgf-beta inhibitor
WO2010099139A3 (en) Combination of an either an anti-igf-ir- antibody or an igf binding protein and a small molecule igf-ir kinease inhibitor
WO2008134752A3 (en) Methods and compositions for the treatment of cancer
WO2009138507A3 (en) Anti-cancer combination therapy
WO2006027693A8 (en) Tumor specific genes and variant rnas and uses thereof as targets for cancer therapy and diagnosis
WO2008148932A3 (en) Glycosylasparaginase for treatment of cancers or inflammatory diseases
WO2008034909A3 (en) Second line treatment of metastatic hormone refractory prostate cancer using satraplatin
WO2012090207A3 (en) Par1 and par2 c-tail peptides and peptide mimetics
WO2005076888A3 (en) Anti-cancer therapies

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07836279

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07836279

Country of ref document: EP

Kind code of ref document: A2